...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: 3 Presentations March 26-March 30, 2020

Here is an H1 2020 version of potential events/presenations, similar to what I've put together in the past. This is mainly based on attendance or presentation at prior events, and is mostly science meetings with some investor conferences mixed in. There is no guarantee that Resverlogix will present at all of the events listed below, but the science meetings for which they have accepted/scheduled presentations are a safe bet. Did I miss any? If so, let me know! Last year, Resverlogix news released about upcoming Q1 2019 conferences on March 11. So maybe we'll get a head up news release around the same time this year. 

Roth Conference March 15-17, 2020; Orange County, CA. Last year they did a webcast in advance of the Roth Conference and made the slide deck available on presentation day. I'm not sure about this year though. https://www.roth.com/Page/Corporate-Access-Conferences

  

BIO-Europe Spring March 23-25, 2020; Paris, France. I don't see Resverlogix on the presenting company list at this time, but things may change. https://informaconnect.com/bioeurope-spring/ 

 

National Kidney Foundation Spring Clinical Meeting March 25-29, 2020; New Orleans, LA. https://www.kidney.org/spring-clinical

Thursday March 26, 2020, 4:45-5:15 PM. Late Breaking Abstract Presentation presented by Dr. Kamyar Kalantar-Zadeh, MD.

Apabetalone reduces Cardiovascular Events in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Recent Acute Coronary Syndrome: A BETonMACE trial report

  

American College Cardiology (ACC) together with World College of Cardiology March 28-30, 2020; Chicago, IL. https://accscientificsession.acc.org/

March 29, 2020, Poster Session 12:00-2:00 PM presented by Dr. Stephen J. Nicholls. https://www.abstractsonline.com/pp8/#!/8992/session/875

1315-168 / 168 - THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL

March 30, 2020, Moderated Poster Session 10:00-10:10 AM presented by Dr. Sylwia Wasiak, PhD. Followed by 5 minutes of moderated Q&A. https://www.abstractsonline.com/pp8/#!/8992/presentation/12275 

1080-05 - EPIGENETIC READER INHIBITOR APABETALONE (RVX-208) COUNTERS PROINFLAMMATORY HYPERACTIVATION OF CD14+ MONOCYTES FROM PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

 

Advances in Alzheimer's and Parkinson's Therapies.  AAT-AD/PD Focus Meeting April 2-5, 2020; Vienna, Austria. https://aat-adpd.kenes.com/

April 2, 2020, Plenary Session. ALZHEIMER’S DRUG DEVELOPMENT PIPELINE:  NOVEL TARGETS AND INNOVATIVE APPROACHES. Presented by Dr. Jeffrey Cummings, MD from 9:30 to 10:00 AM. Abstract available on conference website.

April 3, 2020, Poster Session. THE EPIGENETIC MODULATOR APABETALONE DOWNREGULATES BRAIN ENDOTHELIAL ACTIVATION AND MONOCYTE ADHESION. Presented by Dr. Ewelina Kulikowski, PhD from 4:40-7:00 PM. Abstract available on conference webiste.

April 5, 2020, Symposium. ASSOCIATION OF SERUM ALKALINE PHOSPHATASE ON COGNITIVE FUNCTION IN PATIENTS WITH DIABETES AND ACUTE CORONARY SYNDROME. Presented by Dr. Jan O. Johansson, MD, PhD from 12:25 PM - 12:45 PM. Abstract available on the conference website.

April 5, 2020, Symposium. APABETALONE (AN EPIGENETIC BET-INHIBITOR): A SUB-STUDY OF BETONMACE EVALUATING EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE. Presented by Dr. Ewelina Kulikowski, PhD from 12:45 PM - 01:05 PM. Abstract available on conference website.

 

Vascular Discovery: From Genes to Medicine: May 5-7, 2020; Chicago, IL: Abstract submission period ended January 27, 2020. Full presentation schedule not available yet. https://professional.heart.org/professional/EducationMeetings/MeetingsLiveCME/ATVBPVD/UCM_316902_Vascular-Discovery-From-Genes-to-Medicine.jsp

 

European Atherosclerosis Society (EAS) May 31-June 3, 2020; Geneva, Switzerland: Regular abstract submission period ended December 10, 2019. Late breaking abstract submission will be available between 24-31 March, 2020. Full presentation schedule not available yet. https://eas2020.com/

  

BIO-International June 8-11, 2020; San Diego, CA: No info available yet. https://www.bio.org/events/bio-international-convention

 

American Diabetes Association (ADA) June 12-16, 2020; Chicago, IL: Regular abstract submission period ended January 13th, 2020. The Late Breaking Abstract submission period is open from Feb 3 to March 16, 2020. Full presentation schedule not available yet. https://professional.diabetes.org/scientific-sessions

 

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA): June 6-9, 2020; Milan, Italy. Regular abstract submission period ended January 17th, 2020. The Late Breaking Clinical Trial (LBCT) abstract submission period is open from March 2 to 27, 2020. Full presentation schedule not available yet. https://www.era-edta.org/en/milan2020/ 

 

Share
New Message
Please login to post a reply